REAL‐WORLD TREATMENT PATTERNS, DISCONTINUATION AND CLINICAL OUTCOMES IN PATIENTS WITH B‐CELL LYMPHOPROLIFERATIVE DISEASES TREATED WITH BTK INHIBITORS IN CHINA.

B Backgrounds: b Bruton tyrosine kinaseinhibition (BTKi) is an effective treatment approach for patients with B-cell lymphoproliferative diseases (BLPD). REAL-WORLD TREATMENT PATTERNS, DISCONTINUATION AND CLINICAL OUTCOMES IN PATIENTS WITH B-CELL LYMPHOPROLIFERATIVE DISEASES TREATED WITH BTK INHIBITORS IN CHINA The frequency of BTKi discontinuation varied by regimen, with the higher rate among BTKi combined with CHOP-like regimen-treated patients (60.0% vs. other regimens 41.7%, I P i = 0.027). [Extracted from the article]